Hiring in life sciences? Share your open positions with our professional community. Read more Close

Your cookie settings

This site uses cookies. Some cookies are essential to make the site work and others help us to improve our services. Read more about cookies in our Privacy policy.

Choose your cookie preferences:

Advertisement

[CAR T-cell therapy and bispecific antibodies for relapsed/refractory large B-cell lymphoma].

Created on 07 Jul 2025

Authors

Hideki Goto

Published in

[Rinsho ketsueki] The Japanese journal of clinical hematology. Volume 66. Issue 6. Pages 432-439.

Abstract

While many cases of large B-cell lymphoma (LBCL) can be cured with initial treatment, some patients experience relapse or are refractory to treatment. Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies can be used for relapsed or chemotherapy-refractory LBCL. This review highlights the latest evidence regarding CAR T-cell therapy and bispecific antibodies for relapsed or refractory LBCL.

PMID:
40619226
Bibliographic data and abstract were imported from PubMed on 07 Jul 2025.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Sign in to post a review. Add review
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 25
  • Comments 0

Recommended by

  • No recommendations yet.

Do you recommend this? Please sign in. Yes No

Recommended

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement